Local Coverage Determination (LCD): Bisphosphonates (Intravenous [IV]) and Monoclonal Antibodies in the Treatment of Osteoporosis and Their Other Indications (L32100) Contractor Information Contractor Name First Coast Service Options, Inc. LCD Information Document Information LCD ID L32100 LCD Title Bisphosphonates (Intravenous [IV]) and Monoclonal Antibodies in the Treatment of Osteoporosis and Their Other Indications AMA CPT/ADA CDT Copyright Statement CPT only copyright 2002-2013 American Medical Association. All Rights Reserved. CPT is a registered trademark of the American Medical Association. Applicable FARS/DFARS Apply to Government Use. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. The Code on Dental Procedures and Nomenclature (Code) is published in Current Dental Terminology (CDT). Copyright American Dental Original Effective Date For services performed on or after 10/16/2011 Revision Effective Date For services performed on or after 01/01/2014 Revision Ending Date N/A Retirement Date N/A Notice Period Start Date 09/02/2011 Notice Period End Date N/A
Association. All rights reserved. CDT and CDT-2010 are trademarks of the American Dental Association. CMS National Coverage Policy Language quoted from CMS National Coverage Determination (NCDs) and coverage provisions in interpretive manuals are italicized throughout the Local Coverage Determination (LCD). NCDs and coverage provisions in interpretive manuals are not subject to the LCD Review Process (42 CFR 405.860[b] and 42 CFR 426 [Subpart D]). In addition, an administrative law judge may not review an NCD. See 1869(f)(1)(A)(i) of the Social Security Act. Unless otherwise specified, italicized text represent quotation from one or more of the following CMS sources: The Medicare Program Integrity Manual, Pub. 100-08, Chapter 13, Section 13 The Medicare Benefit Policy Manual, Pub. 100-02, Chapter 15, Section 50 The Medicare Claims Processing Manual, Pub. 100-04, Chapter 17, Section 10 Coverage Guidance Coverage Indications, Limitations, and/or Medical Necessity Indications This LCD addresses incident to drugs that are not self-administered for certain patients with osteoporosis. The other indications for these drugs are also addressed. Osteoporosis is characterized by decreased bone mass and increased fracture risk, most commonly at the spine, hip, and wrist. The diagnosis can be confirmed by a finding of low bone mass, evidence of fracture on x-ray, a history of osteoporotic fracture, or height loss or kyphosis indicative of vertebral fracture. While osteoporosis occurs in both men and women, it is most common among women following menopause. In healthy people, bone formation and resorption are closely linked; old bone is resorbed and replaced by newly formed bone. In postmenopausal osteoporosis, bone resorption exceeds bone formation, leading to bone loss and increased risk of fracture. The World Health Organization (WHO) defines osteoporosis in a postmenopausal woman or a man over the age of 50 as a bone mineral density (BMD) T-score less than or equal to -2.5 at the total hip, femoral neck, or lumbar spine (at least two vertebral levels measured in the posterior-anterior projection, not the lateral projection) as noted below (refer also to LCD for Bone Mineral Density Studies. Normal: T-score above (i.e., better than) or equal to -1.0 Osteopenia: T-score between -1.0 and -2.5 Osteoporosis: T-score below (i.e., worse than) or equal to -2.5 In addition to diagnosis through densitometry, osteoporosis can be diagnosed clinically, regardless of the T-score. The presence of a fragility fracture constitutes a clinical diagnosis of
osteoporosis. It is important to distinguish between risk factors for osteoporosis as defined by BMD and risk factors for osteoporotic fracture. The use of BMD T-scores to assess fracture risk can be markedly improved by combining BMD with information about other risk factors, particularly the woman s age and fracture history. The major risk factors in postmenopausal women are advanced age, genetics, lifestyle factors (e.g., low calcium and vitamin D intake, smoking, and heavy alcohol consumption), thinness, and menopausal status. Because nearly 50% of postmenopausal women in the community over the age of 50 years who suffer an osteoporotic fracture do not have osteoporosis as defined by a BMD test, the WHO developed the fracture risk assessment tool (FRAX) to identify clinical risk factors of patients at high risk for osteoporotic fractures: Age Sex Prior fragility fracture after age 50 History of corticosteroid use (5 mg per day or more for three months or longer) Parental history of hip fracture Rheumatoid arthritis Secondary osteoporosis (e.g., type 1 diabetes, osteogenesis imperfecta in adults, longstanding hyperthyroidism, hypogonadism, premature menopause (before age 40), chronic malabsorption and chronic liver disease) Current smoker Alcohol use of greater than 2 medium glasses of wine or beer per day Body Mass Index (BMI) (less than 21 kg/m2) Other secondary causes of osteoporosis include the following: Oral glucocorticosteroid therapy for longer than 3 months Hypogonadism Transplant history Obesity surgery Malabsorption disease Aromatase therapy for breast cancer Excess urinary calcium excretion Vitamin D deficiency Hypocalcemia Multiple myeloma Endocrine disorders such as hyperthyroidism, Cushing s syndrome, and disorders of collagen structures Renal failure (increase bone resorption, or decreased bone formation leading to renal osteodystrophy) Paget s disease Liver/biliary disease Metastatic cancer involving bone
Medical management focused on lifestyle may be all that is needed for postmenopausal women who are at low risk for osteoporotic fracture. The North American Menopause Society (NAMS) recommends adding osteoporosis drug therapy in the following populations: All postmenopausal women who have had an osteoporotic vertebral or hip fracture All postmenopausal women who have had BMD values consistent with osteoporosis (i.e., T-scores equal to or worse than -2.5) at the lumbar spine, femoral neck, or total hip region In order to be covered by Medicare, a drug or biological must be safe and effective and otherwise reasonable and medically necessary. Drugs and biologicals approved for marketing by the Food and Drug Administration (FDA) are considered safe and effective when used for indications specified in the FDA labeling. The FDA labeling lists the safe and effective indications, dosage, and frequency of the agents. The Centers for Medicare and Medicaid Services (CMS) Medicare Benefit Policy Manual, Pub. 100-02, chapter 15, section 50 states the following: The Medicare program provides limited benefits for outpatient drugs that are furnished incident to a physician s service provided that the drugs are not usually self-administered by the patients who take them. Generally, drugs and biologicals are covered only if all of the following requirements are met: They meet the definition of drugs or biologicals; They are of the type that are not usually self-administered; They meet all of the general requirements for coverage of items as incident to a physician s services; They are reasonable and necessary for the diagnosis or treatment of the illness or injury for which they are administered according to accepted standards of medical practice; They are not excluded as noncovered immunizations; and They have not been determined by the FDA to be less than effective. In addition to FDA approved indications, Medicare may consider coverage of off-label uses based on guidance provided in the Medicare Benefit Policy Manual, Pub. 100-02, chapter 15, section 50.4.2. This manual section indicates the following: Unlabeled Use of Drugs: FDA approved drugs used for indications other than what is indicated on the official label may be covered under Medicare if the contractor determines the use to be medically accepted, taking into consideration the major drug compendia, authoritative medical literature and/or accepted standards of medical practice. These decisions are made by the contractor on a case-by-case basis. If the drug use is not on the FDA label, and is not included in one of the compendium approved by CMS (American Hospital formulary Services (AHFS), Clinical Pharmacology, NCCN Drugs and Biologicals Compendium and/or Thomson Microdedex DrugDex ) and the Medicare Administrative Contractor has not published an LCD or article covering the off-label use, the drug use would not be considered reasonable and necessary, and, therefore not allowed. Not
only does the indication for the use of the drug need to meet medical necessity requirements, but the route of administration is also subject to medical necessity criteria. Contractors must continue to apply the policy that not only is the drug medically reasonable and necessary for any individual claim, but also that the route of administration is medically reasonable and necessary. That is, if a drug is available in both oral and injectable forms, the injectable form of the drug must be medically reasonable and necessary as compared to using the oral form. Medication given by injection (parenterally) is not covered if standard medical practice indicates that the administration of the medication by mouth (orally) is effective and is an accepted or preferred method of administration. Medical necessity is not demonstrated in the cases where a patient has not taken the oral form of a medication before the IV form of the drug, either for patient or provider convenience purposes, or for financial or emotional reasons, and these claims will be denied. Bisphosphonates The following bisphosphonate injections (administered intravenously [IV]) will be considered medically reasonable and necessary when administered as outlined in this LCD. The coverage of IV bisphosphonates must be supported in the medical record. The documentation should include the following information: Criteria for the diagnosis of osteoporosis, and History of treatment as related to progression of disease and ongoing risk factors, and Description of treatment failure, or contraindication, or adverse side effects, of oral or self administered drugs for osteoporosis as applicable to the patient that supports IV therapy in lieu of standard oral treatment protocol. The following IV bisphosphonate injections are considered medically reasonable and necessary when administered as outlined in this LCD: Ibandronate sodium injection (Boniva ) Zoledronic acid injection (Reclast ) Zoledronic acid injection (Zometa ) Boniva is a bisphosphonate that inhibits osteoclast activity and reduces bone resorption and turnover, leading to, on average, a net gain in bone mass. Boniva, like other bisphosphonates administered orally, may cause upper gastrointestinal disorders such as dysphagia, esophagitis, and esophageal or gastric ulcer. Treatment with IV bisphosphonates has been associated with renal toxicity manifested as deterioration in renal function and in rare cases, acute renal failure. Boniva is not recommended for use in patients with severe renal impairment (serum creatinine>200 umol/l [2.3 mg/dl] or creatinine clearance < 30 ml/min). Patients who receive Boniva injection should have serum creatinine measured prior to each dose. Hypocalcemia, hypovitaminosis D and other disturbances of bone and mineral metabolism must be effectively
treated before starting therapy. Patients receiving this therapy must take supplemental calcium and vitamin D. Boniva injection must only be administered intravenously by a healthcare professional. Given the oral equivalent and the availability of Boniva tablets, and the Medicare manual language on the reasonable and necessary criteria for route of admission, the IV administration is allowed under the following circumstances: Patient has a diagnosis of esophageal stricture, achalasia, or other severe esophageal dysmotility disorder; OR Patient has a history of severe malabsorption making use of oral bisphosphonates ineffective; OR Patient has an inability to stand or sit upright for 60 minutes; OR Patient has documented adverse effects following the initiation of treatment of the oral form of the medication that required the withdrawal of the oral form of the medication. FDA Indication for Boniva Injection: Treatment of osteoporosis in postmenopausal women Off-label Indications for Boniva Injection: o Corticosteroid-induced osteoporosis o Paget s disease o Bone metastases in patients with prostate cancer Zoledronic acid (Reclast and Zometa ) is a bisphosphonic acid, which is an inhibitor of osteoclastic bone resorption. Zoledronic acid binds to the bone matrix, which decreases osteoclastic activity, prevents bone resorption and skeletal calcium release induced by various stimulatory factors released by tumors. FDA Indications for Reclast Injection: Treatment of osteoporosis in postmenopausal women Treatment of osteoporosis in men Treatment and prevention of glucocorticoid-induced osteoporosis in men and women who are either initiating or continuing systemic glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and who are expected to remain on glucocorticoids for at least 12 months Treatment for Paget s disease of the bone with elevations in serum alkaline phosphatase of two times or higher than upper limit of the age-specific normal reference range, or those who are symptomatic, or those at risk for complications from their disease, to induce remission (normalization of serum alkaline phosphatase). FDA Indications for Zometa Injection:
Hypercalcemia of malignancy Multiple myeloma Bone metastases from solid tumors in conjunction with standard antineoplastic therapy, including bone metastases from multiple myeloma, breast carcinoma, prostate carcinoma, and other solid tumors Note: Prostate cancer should have progressed after treatment with at least one hormonal therapy. Off-label Indication for Zometa Injection: o Drug-induced osteopenia, secondary to androgen-deprivation therapy in prostate cancer patients (prophylaxis). Monoclonal Antibodies - RANK ligand (RANKL) Inhibitors: The following monoclonal antibodies injections (administered subcutaneously [SQ]) will be considered medically reasonable and necessary when administered as outlined in this LCD. The coverage of SQ monoclonal antibodies must be supported in the medical record. The documentation should include the following information: Criteria for the diagnosis of osteoporosis, and History of treatment as related to progression of disease and ongoing risk factors, and Description of treatment failure, or contraindication, or adverse side effects of oral or self administered drugs for osteoporosis as applicable to the patient that supports monoclonal antibodies via SQ injection therapy in lieu of standard oral treatment protocol. Denosumab (Prolia and Xgeva ) binds to RANKL, a transmembrane of soluble protein essential for the formation, function, and survival of osteoclasts, the cells responsible for bone resorption. Denosumab prevents RANKL from activating its receptor, RANK, on the surface of osteoclasts and their precurseors. Prevention of the RANKL/RANK interaction inhibits osteoclast formation, function, and survival, thereby decreasing bone resorption and increasing bone mass and strength in both cortical and trabecular bone. Prolia (denosumab) is a human IgG2 monoclonal antibody with affinity and specificity for human RANKL (receptor activator of nuclear factor kappa B ligand). It is produced in genetically engineered mammalian (Chinese hamster ovary) cells. Prolia is given in a 1 ml single-use prefilled syringe with 60 mg denosumab and is administered every 6 months as a subcutaneous (SQ) injection into the upper arm, the upper thigh, or abdomen by a health care professional. Xgeva (denosumab) is a human IgG2 monoclonal antibody that binds to human RANKL that is produced in genetically engineered mammalian (Chinese hamster ovary) cells. Xgeva is
administered every 4 weeks as a 120 mg SQ injection into the upper arm, upper thigh, or abdomen by a health care professional. For treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity, an additional 120 mg dose is administered on days 8 and 15 of the first month of therapy. FDA indications for Prolia : Treatment of postmenopausal women with osteoporosis at high risk for fracture Treatment to increase bone mass in men with osteoporosis at high risk for fracture Treatment of bone loss in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer Treatment of bone loss in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer High risk for fracture is defined as a history of osteoporotic fracture; or multiple risk factors for fracture; or patients who failed or are intolerant of other available osteoporosis therapy. FDA indication for Xgeva : Prevention of skeletal related events in patients with bone metastasis from solid tumors. Treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity. Limitations: Combination use of a bisphosphonate and a monoclonal antibody for the treatment of osteoporosis during an episode of care is not considered reasonable and necessary, and therefore, is not covered. Combination use of IV and/or oral forms of bisphosphonate therapy as treatment for osteoporosis during an episode of care is not covered. An episode of care includes the duration and frequency of the IV drugs in accordance with FDA labels. Hypocalcemia, hypovitaminosis D, and other disturbances of bone and mineral metabolism must be effectively treated before starting therapy. Patients must receive supplemental calcium and vitamin D. For duration of treatment regarding the safety and effectiveness of the drugs listed in this LCD, the following information applies: IV Boniva is based on data from clinical trials of 1 year duration. Prolia is based on data from clinical trials of 2 years duration
Reclast is based on data from clinical trials of 3 years duration Xgeva is based on data from clinical trials of median duration on-study of 13 months. Zometa is based on data from clinical trials of 2 years duration. The optimal duration of the use of the drugs listed in this LCD has not been determined. It is expected that treatment with these drugs in a Medicare beneficiary meets the evidence-based peer reviewed literature and standards of care in the medical community. Boniva is available in oral and IV forms. The IV form will be considered reasonable and necessary only for patients for whom oral therapy cannot be tolerated. Boniva Injection is contraindicated for the following conditions: Severe renal impairment defined as patients with serum creatinine >200µmol/L [2.3 mg/dl] or creatinine clearance measured or estimated <30 ml/min Known hypersensitivity to Boniva injections or to any of its excipients Uncorrected hypocalcemia Reclast used for prevention without a confirmed diagnosis of osteoporosis in postmenopausal women will not be covered because it is not considered medically reasonable and necessary in the diagnosis and treatment of a specific illness or injury as defined in the Social Security Act, Section 1862(a)(1)(A) and as stated in CMS Publication 100-02, Medicare Benefit Policy Manual, chapter 15, section 50.4 Reclast is contraindicated in the following conditions: Hypocalcemia Hypersensitivity to the active substance (zoledronic acid) or to any of the excipients Pregnancy and lactation Patients receiving Zometa Severe renal impairment defined as patients with serum creatinine clearance measured or estimated <35 ml/min Zometa is contraindicated for the following conditions: Hypersensitivity to zoledronic acid or any component of Zometa Pregnancy and lactation Prolia is contraindicated for the following condition: Hypocalcemia
Xgeva is not indicated for the following indication: Prevention of skeletal related events in patients with multiple myeloma and other cancers of the blood Coding Information Bill Type Codes: Contractors may specify Bill Types to help providers identify those Bill Types typically used to report this service. Absence of a Bill Type does not guarantee that the policy does not apply to that Bill Type. Complete absence of all Bill Types indicates that coverage is not influenced by Bill Type and the policy should be assumed to apply equally to all claims. N/A Revenue Codes: Contractors may specify Revenue Codes to help providers identify those Revenue Codes typically used to report this service. In most instances Revenue Codes are purely advisory; unless specified in the policy services reported under other Revenue Codes are equally subject to this coverage determination. Complete absence of all Revenue Codes indicates that coverage is not influenced by Revenue Code and the policy should be assumed to apply equally to all Revenue Codes. N/A CPT/HCPCS Codes Group 1 Paragraph: J3489 Injection, zoledronic acid,1 mg (Reclast and Zometa) Group 1 Codes: J0897 INJECTION, DENOSUMAB, 1 MG J1740 INJECTION, IBANDRONATE SODIUM, 1 MG ICD-9 Codes that Support Medical Necessity Group 1 Paragraph: HCPCS Code J1740 (Boniva ) Group 1 Codes:
198.5 SECONDARY MALIGNANT NEOPLASM OF BONE AND BONE MARROW 731.0 OSTEITIS DEFORMANS WITHOUT BONE TUMOR 733.01 SENILE OSTEOPOROSIS 733.09* OTHER OSTEOPOROSIS ADRENAL CORTICAL STEROIDS CAUSING ADVERSE EFFECTS IN E932.0* THERAPEUTIC USE Group 1 Medical Necessity ICD-9 Codes Asterisk Explanation: **When reporting ICD-9- CM code 733.09, the ICD-9-CM coding manual requires a dual diagnosis. In this regard, when reporting ICD-9-CM code 733.09 (other, osteoporosis), ICD-9-CM code E932.0 (adrenal cortical steroids) must also be reported. Group 2 Paragraph: HCPCS Code J3489 (Zometa ) Group 2 Codes: 198.5 SECONDARY MALIGNANT NEOPLASM OF BONE AND BONE MARROW 203.00-203.02 MULTIPLE MYELOMA, WITHOUT MENTION OF HAVING ACHIEVED REMISSION - MULTIPLE MYELOMA, IN RELAPSE 275.42 HYPERCALCEMIA 733.90 DISORDER OF BONE AND CARTILAGE UNSPECIFIED Group 3 Paragraph: HCPCS Code J3489 (Reclast ) Group 3 Codes: 731.0 OSTEITIS DEFORMANS WITHOUT BONE TUMOR 733.01 SENILE OSTEOPOROSIS 733.09* OTHER OSTEOPOROSIS ADRENAL CORTICAL STEROIDS CAUSING ADVERSE EFFECTS IN E932.0* THERAPEUTIC USE Group 3 Medical Necessity ICD-9 Codes Asterisk Explanation: **When reporting ICD-9- CM code 733.09, the ICD-9-CM coding manual requires a dual diagnosis. In this regard, when reporting ICD-9-CM code 733.09 (other, osteoporosis), ICD-9-CM code E932.0 (adrenal cortical steroids) must also be reported. Group 4 Paragraph: HCPCS Codes J0897 (Prolia ) Group 4 Codes: 733.00-733.03 OSTEOPOROSIS UNSPECIFIED - DISUSE OSTEOPOROSIS 733.09 OTHER OSTEOPOROSIS 733.90 DISORDER OF BONE AND CARTILAGE UNSPECIFIED Group 5 Paragraph: For treatment of bone loss in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer, ICD-9-CM code 733.90 is reported with V10.3 and V07.52 Group 5 Codes:
V07.52 USE OF AROMATASE INHIBITORS V10.3 PERSONAL HISTORY OF MALIGNANT NEOPLASM OF BREAST Group 6 Paragraph: For treatment of bone loss in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer, ICD-9-CM code 733.90 is reported with V10.46 and V58.69 Group 6 Codes: V10.46 PERSONAL HISTORY OF MALIGNANT NEOPLASM OF PROSTATE V58.69 LONG-TERM (CURRENT) USE OF OTHER MEDICATIONS Group 7 Paragraph: HCPCS Codes J0897 (Xgeva ) Group 7 Codes: 198.5 SECONDARY MALIGNANT NEOPLASM OF BONE AND BONE MARROW NEOPLASM OF UNCERTAIN BEHAVIOR OF BONE AND ARTICULAR 238.0 CARTILAGE ICD-9 Codes that DO NOT Support Medical Necessity N/A General Information Associated Information Documentation Requirements For all drugs outlined in this LCD: Medical record documentation must be maintained by the ordering/referring physician or the nonphysician practitioner and should include the following, and be available to Medicare upon request: The record must demonstrate the medical need for the use of the drug by clearly indicating the condition for which the drug is being used. The medical record must indicate that the treatment is based on diagnostic information and lab work completed to confirm the indications for use of the drug. The specific signs and symptoms must be documented to substantiate the FDA labeled or the FDA off labeled indications for the drug usage. For the osteoporosis indications for the drugs outlined in this LCD, the medical record must indicate that the patient has been examined for secondary causes of osteoporosis. An indication that the patient has been advised to take adequate calcium and vitamin D supplementation.
For the osteoporosis indications for the drugs outlined in this LCD, an indication that the patient has been advised to practice regular weight bearing and muscle strengthening exercise to reduce risk of falls and fracture, and to avoid tobacco smoking and excessive alcohol intake. The medication administration record (MAR) including the name, date, time, route and dose of the drug administered to the patient. A statement that demonstrates oral health was discussed with the patient. This documentation is usually found in the history and physical and/or in the office/progress notes of the medical record. In addition, the MAR should be included indicating the name, date, time, route and amount of drug administered. The physician order should also be included. In addition, specific documentation is also required as outlined below: Bisphosphonate therapy: The following bisphosphonate injections (administered IV) are considered medically reasonable and necessary when administered as outlined in this LCD. The coverage of IV bisphosphonates must be supported in the medical record. The documentation should include the following information: Criteria for the diagnosis of osteoporosis, and History of treatment as related to progression of disease and ongoing risk factors, and Description of treatment failure of oral or self administered drugs for osteoporosis as applicable to the patient that supports IV therapy in lieu of standard oral treatment protocol. An indication that the serum creatinine was measured prior to the administration of the drug. An indication that the oral health of the patient was discussed Boniva The documentation must clearly state why IV Boniva is being given as opposed to the oral form of the drug. Documentation should demonstrate if one of the following apply: Patient has a diagnosis of esophageal stricture, achalasia, or other severe esophageal dysmotility disorder; OR Patient has a history of severe malabsorption making use of oral bisphosphonates ineffective; OR Patient has an inability to stand or sit upright for 60 minutes; OR Patient had adverse side effects secondary to oral form of the drug that required the withdrawal of the oral from of the medication. An indication that the serum creatinine was measured before Boniva was administered An indication that the patient does not have severe renal impairment (patients with severe renal impairment with serum creatinine >200 µmol/l [2.3 mg/dl] or creatinine clearance measured or estimated <30 ml/min should not receive Boniva injection) Documentation to support that the drug was administered per IV route by a healthcare professional with a 3mg/3 ml bolus over 15 to 30 seconds every three months
Reclast - All patients An indication that the patient received adequate hydration prior to treatment An indication that the patient has a creatinine clearance of 35 ml/min or better Documentation to support that the drug was administered one time in a year per IV route by a healthcare professional with 5 mg Reclast infused IV over no less than 15 minutes given over a constant infusion rate with a 10 ml normal saline flush of the IV line following the infusion Reclast for Glucocorticoid-Induced Osteoporosis in Men and Women (must meet above criteria also) An indication that the patient is either initiating or continuing to take system glucocorticoids in a daily dosage of 7.5 mg or greater of prednisone and who are expected to remain on glucocorticoids for at least 12 months An indication that the patient is taking at least 1200 mg calcium and 800-1000 IU vitamin D per day Reclast for Women or Men with Osteoporosis An indication that the patient is taking at least 1200 mg calcium and 800-1000 IU vitamin D per day Reclast for Paget s Disease An indication that the patient has been instructed to take 1500 mg elemental calcium daily in divided doses (750 mg two times per day, or 500 mg three times per day) and 800 IU vitamin D per day, particularly in the 2 weeks following the administration of Reclast An indication that the patient has one of the following: o An elevated serum alkaline phosphatase of two times or higher than the upper limit of the agespecific normal reference range, or o The patient is symptomatic, or o The patient is at risk for complications from the disease, to induce remission (normalization of serum alkaline phosphotase) prior to treatment with Reclast Reclast for Re-Treatment of Paget s Disease An indication that the patient is experiencing a relapse based on serum alkaline phosphatase, or An indication that the patient has failed to achieve normalization of their serum alkaline phosphatase, or An indication that the patient has symptoms as dictated by current standard medical practice. Zometa An indication that the patient is not on any other bisphosphonate medication(s)
Documentation to support that the drug was administered per IV route by a healthcare professional with a dosage amount not exceeding 4 mg administered for no less than 15 minutes An indication that the renal status of the patient has been monitored Zometa for Hypercalcemia of Malignancy An indication that the patient has an albumin-corrected serum calcium of 12 mg/dl (3.0 mmol/l) The date of the last treatment must be indicated Zometa for Multiple Myeloma and Metastatic Bone Lesions of Solid Tumors An indication that for the patient with a creatinine clearance of > 60 ml/min, a 4 mg IV infusion over no less than 15 minutes was administered every 3-4 weeks by a healthcare provider An indication that the patient was coadministered oral calcium supplements of 500 mg and a multiple vitamin containing 400 IU of vitamin D per day Prolia Prolia for Women with Postmenopausal Osteoporosis An indication that the patient meets the definition of high risk for fracture, or An indication that the patient has failed or is intolerant of other available osteoporotic therapy An indication that the patient received a single dose of 60 mg SQ Prolia which was administered by a healthcare professional into the upper arm, the upper thigh or the abdomen once in 6 months An indication that the patient was instructed to take 1000 mg of calcium and at least 400 IU of vitamin D per day Prolia for Men with Osteoporosis An indication that the patient meets the definition of osteoporosis with high risk for fracture, or An indication that the patient has failed or is intolerant of other available osteoporotic therapy An indication that the patient received a single dose of 60 mg SQ Prolia which was administered by a healthcare professional into the upper arm, the upper thigh, or the abdomen once in 6 months. An indication that the patient was instructed to take 1000 mg of calcium and at least 400 IU of vitamin D per day Prolia for Treatment of Bone Loss in Women Receiving Adjuvant Aromatase Inhibitor Therapy for Breast Cancer An indication that the patient is a woman receiving adjuvant aromatase inhibitor therapy for breast cancer An indication that the patient received a single dose of 60 mg SQ Prolia which was administered by a healthcare professional into the upper arm, the upper thigh or the abdomen
once in 6 months An indication that the patient was instructed to take 1000 mg of calcium and at least 400 IU of vitamin D per day Prolia for Treatment of Bone Loss in Men Receiving Androgen Deprivation Therapy for Nonmetastatic Prostate Cancer An indication that the patient is a man receiving androgen deprivation therapy for prostate cancer An indication that the patient received a single dose of 60 mg SQ Prolia which was administered by a healthcare professional into the upper arm, the upper thigh or the abdomen once in 6 months An indication that the patient was instructed to take 1000 mg of calcium and at least 400 IU of vitamin D per day Xgeva Xgeva for the prevention of skeletal-related events in patients with Bone Metastasis from solid tumors An indication that the patient received a single dose dose of 120 mg SQ Xgeva which was administered by a healthcare professional into the upper arm, the upper thigh or the abdomen once every 4 weeks An indication that the patient is taking calcium and vitamin D supplements as necessary to treat or prevent hypocalcemia Xgeva for the treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity. An indication that the patient received a single dose of 120 mg SQ Xgeva every 4 weeks with additional 120 mg doses on days 8 and 15 of the first month of therapy An indication Xgeva was administered by a healthcare professional into the upper arm, the upper thigh or the abdomen An indication that the patient is taking calcium and vitamin D supplements as necessary to treat or prevent hypocalcemia Utilization Guidelines It is expected that these services would be performed as indicated by current literature and/or standards of practice and should follow the guidelines for administration and safety found in the FDA approved labels for these drugs. When services are performed in excess of established
parameters, they may be subject to medical review for medical necessity. Boniva Boniva injection must be administered by intravenous route only by a healthcare professional The recommended dose of Boniva injection is 3 mg/3 ml IV bolus over 15 to 30 seconds once every three months Patients with severe renal impairment with serum creatinine >200 µmol/l (2.3 mg/dl) or creatinine clearance measured or estimated <30 ml/min should not receive Boniva injection Patients taking Boniva must receive supplemental calcium and vitamin D Reclast Reclast contains the same active ingredient found in Zometa. A patient that is already receiving Zometa should not be treated with Reclast. Patients must receive adequate hydration prior to the administration of Reclast For patients with creatinine clearance 35 ml/min the recommended dose of Reclast is 5 mg infused intravenously once a year over no less than 15 minutes given over a constant infusion rate with a 10 ml normal saline flush of the IV line following the infusion Glucocorticoid-Induced Osteoporosis The recommended regimen is a 5 mg of Reclast IV infused once a year over no less than 15 minutes given over a constant infusion rate with a 10 ml normal saline flush of the IV line following the infusion. An average of at least 1200 mg calcium and 800-1000 IU vitamin D per day is recommended for patients with glucocorticoid-induced osteoporosis receiving Reclast. Osteoporosis in Postmenopausal Women and Men For treatment of osteoporosis in postmenopausal women and men, 5 mg of Reclast IV infused once a year over no less than 15 minutes given over a constant infusion rate is recommended with a 10 ml normal saline flush of the IV line following the infusion. 1200 mg calcium and 800-1000 IU vitamin D per day. Paget s Disease The recommended dose is 5 mg of Reclast IV infused once a year over no less than 15 minutes given over a constant infusion rate with a 10 ml normal saline flush of the IV line following the infusion. To reduce the risk of hypocalcemia, all patients with Paget s disease should receive 1500 mg elemental calcium daily in divided doses (750 mg two times a day, or 500 mg three times a day) and 800 IU vitamin D daily, particularly in the 2 weeks following the administration of Reclast. Zometa
Zometa contains the same active ingredient found in Reclast. A patient that is already receiving Zometa should not be treated with Reclast. A single dose of Zometa should not exceed 4mg and must be given intravenously for no less than 15 minutes. Retreatment with Zometa 4 mg may be considered if serum calcium does not return to normal or remain normal after treatment. It is recommended that a minimum of 7 days elapse before re-treatment to allow for full response to the initial dose. Renal function must be carefully monitored in all patients receiving Zometa and possible deterioration in renal function must be assessed prior to re-treatment with Zometa Hypercalcemia of Malignancy Zometa is indicated for the treatment of hypercalcemia of malignancy defined as an albumincorrected serum calcium 12 mg/dl [3.0 mmol/l]. The maximum recommended dose of Zometa for this indication is 4 mg dose given as a single-dose IV infusion over no less than 15 minutes. Patients should have their serum creatinine assessed prior to each treatment. Patients should be adequately hydrated prior to the administration of Zometa. Retreatment may be considered if serum calcium does not return to normal or remain normal after the initial treatment. A minimum of 7 days should elapse prior to retreatment to allow for full response to the initial dose. Multiple Myeloma and Metastatic Bone Lesions of Solid Tumors The recommended dose of Zometa for these indications for patients with creatinine clearance >60 ml/min is 4 mg infused over no less than 15 minutes every 3 to 4 weeks. Patients should take an oral calcium supplement of 500 mg and a multiple vitamin containing 400 IU of Vitamin D daily. Monoclonal Antibodies - RANK ligand (RANKL) Inhibitors: Prolia Postmenopausal Women with Osteoporosis at High Risk for Fracture Men with Osteoporosis at High Risk for Fracture Prolia for Treatment of Bone Loss in Women Receiving Adjuvant Aromatase Inhibitor Therapy for Breast Cancer Prolia for Treatment of Bone Loss in Men Receiving Androgen Deprivation Therapy for Nonmetastatic Prostate Cancer
Prolia is a single dose 60 mg subcutaneous (SQ) injection administered by a healthcare professional into the upper arm, the upper thigh, or the abdomen once every six months. Patients receiving Prolia are instructed to take 1000 mg of calcium and at least 400 IU of vitamin D per day. Xgeva Prevention of Skeletal-Related Events in Patients with Bone Metastisis from Solid Tumors Xgeva is a single dose of 120 mg SQ injection administered by a healthcare professional into the upper arm, the upper thigh, or the abdomen once every 4 weeks. Patients receiving Xgeva should take calcium and vitamin D as necessary to treat or prevent hypocalcemia. Treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity Xgeva is a single dose of 120 mg SQ injection administered by a healthcare professional into the upper arm, the upper thigh, or the abdomen once every 4 weeks, with additional 120 mg doses on days 8 and 15 of the first month of therapy. Patients receiving Xgeva should take calcium and vitamin D as necessary to treat or prevent hypocalcemia. Sources of Information and Basis for Decision American College of Rheumatology. (2008). New NOF guidelines and the WHO fracture assessment tool or FRAX. Retrieved from: http://www.rheumatology.org/publications/hotline/03_18_flax.asp American College of Rheumatology. (N.D.). Glucocorticoid-induced osteoporosis. Retrieved from: http://www.rheumatology.org/publications/hotline/03_18_flax.asp Boniva (ibandronate sodium) prescribing information. (2010). Genentech, U.S.A., Inc. Clinical Pharmacology Web site. (2011). Denosumab. Retrieved from: http://clinicalpharmacology.com Clinical Pharmacology Web site. (2011). Ibandronate sodium. Retrieved from: http://clinicalpharmacology.com Clinical Pharmacology Web site. (2011). Zoledronic acid. Retrieved from: http://clinicalpharmacology.com North American Menopause Society, (2010). Management of osteoporosis in postmenopausal women: 2010 position statement. Retrieved from:
http://www.medscape.com/viewarticle/714984_print Prolia (denosumab) prescribing information. (2010). Amgen, Inc. Prolia (denosumab) prescribing information. (2011). Amgen, Inc. Prolia (denosumab) prescribing information. (2012). Amgen, Inc. Reclast (zoledronic acid) Injection prescribing information. (2011). Novartis Pharmaceuticals, Corp. World Health Organization (2007). WHO Scientific Group on the Assessment of Osteoporosis at Primary Health Care Level. Summary meeting report, Brussels, Belgium, May 5-7, 2004. Retrieved from http://www.worldhealthorganization.org Xgeva (densoumab) prescribing information. (2010). Amgen, Inc. Xgeva (densoumab) FDA label. (2013). http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125320s094lbl.pdf. Zometa (zoledronic acid) Injection prescribing information. (2011). Novartis Pharmaceuticals, Corp. Revision History Information Please note: Most Revision History entries effective on or before 01/24/2013 display with a Revision History Number of "R1" at the bottom of this table. However, there may be LCDs where these entries will display as a separate and distinct row. Revision History Date 01/01/2014 R8 Revision History Number Revision History Explanation Removed all references to Jurisdiction 9(J9)from LCD text. Reason(s) for Change Other (Removed all references to Jurisdiction 9(J9)from LCD text.) 01/01/2014 R7 Revision Number: 6 Publication: January 2014 Connection LCR B2014-008 Explanation of revision: Annual 2014 HCPCS Update. HCPCS code Q2051 was deleted and replaced with HCPCS code J3489. The effective date of this revision is based on date of service. Revisions Due To CPT/HCPCS Code Changes
10/14/2013 R6 07/01/2013 R5 07/01/2013 R4 09/01/2012 R3 Revision Number: 5 Publication: September 2013 Connection LCR B2013-090 Explanation of revision: The Indications and Limitations of Coverage and/or Medical Necessity section of the LCD has been revised to add a new FDA approved indication for Xgeva. The ICD-9 Codes that Support Medical Necessity section, subtitled HCPCS Codes J0897 (Xgeva ) was revised to add diagnosis code 238.0 (Neoplasm of uncertain behavior of bone and articular cartilage) to correspond with the new FDA approved indication. In addition, the Documentation Requirements, Utilization Guidelines, Sources of Information and Basis for Decision sections of the LCD were updated. The effective date of this revision is for claims processed on or after 10/14/2013, for dates of service on or after 06/13/13. CPT/HCPCS Section additional information added to the paragraphg section Revision Number: 4 Publication: June 2013 Connection LCR B2013-072 Explanation of Revision: Based on CR 8286 (Quarterly HCPCS Drug/Biological Code Changes-July 2013 Update)/CR 8291 (July Update to the CY 2013 MPFSDB)/CR 8328 (July 2013 Update of the ASC payment System), HCPCS codes J3487 and J3488 received status indicator I (not valid for Medicare purposes) and were replaced with HCPCS code Q2051. Therefore, the CPT /HCPCS Codes and ICD-9 Codes that Support Medical Necessity sections of the LCD were updated to remove HCPCS codes J3487 and J3488 and add HCPCS code Q2051. The effective date of this revision is based on date of service. Explanation of Revision: Updated the Indications and Limitations of Coverage New/Updated Technology Revisions Due To ICD-9-CM Code Changes Revisions Due To CPT/HCPCS Code Changes Revisions Due To CPT/HCPCS Code Changes Other
09/01/2012 R2 and/or Medical Necessity section of the LCD to add a new FDA approved indication for Prolia. In addition, the Documentation Requirements, Utilization Guidelines, and Sources of Information and Basis for Decision sections of the LCD were updated. The effective date of this revision is based on date of service. Most recent LCD version approved for display. Revision Number:3 Start Date of Comment Period:N/A Start Date of Notice Period:02/01/2013 Revision Effective Date:09/01/2012 LCR B2012-077 January 2013 Connection Other 09/01/2012 R1 Explanation of Revision: Updated the Indications and Limitations of Coverage and/or Medical Necessity section of the LCD to add a new FDA approved indication for Prolia. In addition, the Documentation Requirements, Utilization Guidelines, and Sources of Information and Basis for Decision sections of the LCD were updated. The effective date of this revision is based on date of service. Revision Number: 2 Start Date of Comment Period:N/A Start Date of Notice Period:05/01/2012 Revision Effective Date : 05/01/2012 N/A LCR B2012-045 April 2012 Connection Explanation of Revision: Updated the Indications and Limitations of Coverage and/or Medical Necessity and ICD-9 Codes that Support Medical Necessity sections of the LCD to add two indications, clinical trial information listed in the package insert, and diagnosis codes for Prolia. Updated the ICD-9 Codes that Support Medical Necessity section of the LCD for Boniva, to
add diagnosis codes for two indications listed in the LCD. In addition, the Documentation Requirements section of the LCD was updated. The effective date of this revision is for claims processed on or after 05/01/2012, for dates of service on or after 10/16/11. Revision Number:1 Start Date of Comment Period:N/A Start Date of Notice Period:01/01/2012 Revision Effective Date:01/01/2012 LCR B2012-021 December 2011 Connection Explanation of Revision: Annual 2012 HCPCS Update. Deleted unlisted HCPCS code J3590 and HCPCS code C9272 and replaced with HCPCS code J0897. Changed Contractor Determination Number to J0897. The effective date of this revision is based on date of service. Revision Number Original Start Date of Comment Period:06/03/2011 Start Date of Notice Period:09/02/2011 Original Effective Date:10/16/2011 LCR B2011-097 September 2011 Connection Associated Documents 11/21/2011 - The following CPT/HCPCS codes were deleted: C9272 was deleted from Group 1 Attachments Comment Summary 6/3/11-7/18/11 (a comment and response document) coding guidelines effec 1/1/14 Related Local Coverage Documents N/A Related National Coverage Documents N/A Public Version(s)
Updated on 04/24/2014 with effective dates 01/01/2014 - N/A Updated on 12/17/2013 with effective dates 01/01/2014 - N/A Updated on 09/18/2013 with effective dates 10/14/2013-12/31/2013 Updated on 07/03/2013 with effective dates 07/01/2013-10/13/2013 Updated on 06/28/2013 with effective dates 07/01/2013 - N/A Updated on 02/21/2013 with effective dates 09/01/2012-06/30/2013 Updated on 01/31/2013 with effective dates 09/01/2012 - N/A Medicare Part B local coverage determination (LCD) comment summary LCD Number J1740 Contractor Name First Coast Service Options, Inc. Contractor Number 09102 - Florida 09202 - Puerto Rico 09302 - U.S. Virgin Islands Contractor Type MAC Part B LCD Title Bisphosphonates (Intravenous [IV]) and Monoclonal Antibodies in the Treatment of Osteoporosis and Their Other Indications AMA CPT Copyright Statement CPT codes, descriptions, and other data only are copyright 2010 American Medical Association (or such other date of publication of CPT). All Rights Reserved. Applicable FARS/DFARS Clauses Apply. Start Date of Comment Period: 06/03/2011 End Date of Comment Period:
07/18/2011 Comments received: Comment #1: Several recommendations were made to change some of the language under the Indications and Limitations of Coverage and/or Medical Necessity section of the LCD below the headings of Bisphosphonates and also Monoclonal Antibodies. Contractor response #1: The language has been evaluated and was found to be congruent with the FDA-approved drug labels. Comment #2: The LCD lists the duration of Xgeva and Boniva as being based on data from clinical trials of 12 months. Xgeva should have its own bullet and it should state the duration from the time of the first clinical trial. The pivotal phase 3 skeletal-related event (SRE) studies were event driven studies without pre-specified study duration. Time from first patient enrollment to the primary analysis was between 34 and 41 months. Therefore, the LCD should state the following: Xgeva is based on data from clinical trials ranging from 34 to 41 months. Contractor response #2: According to the FDA-approved package insert under the heading of Clinical Trials Experience The median duration of exposure to Xgeva was 12 months (range: 0.1 41) and median duration on-study was 13 months (range: 0.1 41). The LCD has been changed to list Xgeva in a separate bullet with a median duration on study of 13 months as it is listed in the FDA-approved package insert. Comment #3: Under the Indications and Limitations of Coverage and/or Medical Necessity section of the LCD below the heading of Boniva, the following is stated: Given the oral equivalent and the availability of Boniva tablets, and the Medicare manual language on the reasonable and necessary criteria for route of administration, the IV administration is allowed under the
following circumstances: This statement should be changed to state that some of this criteria should be documented and this section should include dyspepsia and medication-induced chest pain, and also oral medication intolerance. There are GI exclusions listed based on anatomical diagnostic studies. Intolerance is mentioned elsewhere, but maybe it should be mentioned here as well. Providers might fear just documenting GI intolerance won t be enough (some patients have significant episodes of chest pain or dyspepsia following the ingestion of these oral drugs. Additional clinical indications need to be added to the LCD to justify the need for IV Boniva, including but not limited to previous intolerance to PO bisphosphonate, dyspepsia, GERD, PUD, Barrett s esophagus, inability to swallow, history of non-cardiac chest pain, and dementia. The approved indications are too restrictive, and are anatomic diagnoses that are difficult and expensive to definitively diagnose. Most importantly, these restrictive diagnoses will not pertain to most of our patients for whom PO bisphosphonates are contraindicated. Contractor response #3: Wording under the Indications and Limitations of Coverage and/or Medical Necessity section of the LCD below the heading of Boniva the following was revised to include the following indication: Patient had documented adverse side effects secondary to the oral form of the drug that required the withdrawal of the oral form of the medication. Comment #4: In the section listed as the monoclonal antibodies the following is listed: failed IV therapies.. but the next sentence in lieu of oral therapy. Maybe the IV should be left out as it is confusing? Contractor response #4: The LCD language was changed to remove the reference to IV therapies. Comment #5: Under the Indications and Limitations of Coverage and/or Medical Necessity section of the LCD the FRAX assessment is listed as an indication, however, the FRAX assessment takes too long to perform. Is FRAX a tool that physicians in MAC J9 can use to diagnose osteoporosis?
In reviewing the draft LCD, there is no mention of using the FRAX criteria for determining whether a patient is a candidate for bisphosphonate therapy for osteoporosis. In patients whose T score is greater than 2.5, additional risk factors for fractures may be present that are brought out in using the FRAX criteria calculation. I believe it should be included in the list of criteria that can be met to qualify a patient for IV bisphosphonate treatment for osteoporosis. Contractor response #5: It is not the intention of the LCD to require the performance of the FRAX assessment for the diagnosis of osteoporosis but rather to include information regarding the methods used for the assessment of patients treated for osteoporosis. Comment #6: Xgeva is listed as contraindicated for prevention of skeletal-related events in patients with multiple myeloma. However, The FDA-approved package insert states the following: Xgeva has no contraindications. Xgeva is not indicated for the prevention of skeletal-related events in patients with multiple myeloma. Contractor response #6: The language has been changed to read as follows: Xgeva is not indicated for the prevention of skeletal-related events in patients with multiple myeloma. Comment #7: The LCD lists the dosage as follows: Xgeva is available in a single dose vial containing 120mg in 1.7ml. Physician orders for Xgeva are expected to be written for a specific dose in mg and typically would not state the volume when dealing with a single dose vial. The concern is that a reviewer may deny a claim based on lack of information if the volume of the injection is not specifically documented. Please do not state the 1.7ml in the LCD, but instead list the following: a single dose of 120mg SQ Xgeva. Contractor response #7: The volume listed for Xgeva has been removed from the LCD. Comment #8: Is Xgeva covered for prostate cancer?
Contractor response #8: Xgeva is covered for the FDA-approved indication listed in the package insert which states the following: Xgeva is indicated for the prevention of skeletal-related events in patients with bone metastases from solid tumors. Providers are instructed to report the ICD-9-CM Code listed in the LCD, 198.5, secondary malignant neoplasm of bone and bone marrow, for Xgeva. Comment # 9: Current language in the Documentation Requirements Section of the LCD states the following: Prolia for Women with Postmenopausal Osteoporosis An indication that the patient meets the definition of high risk for fracture, or An indication that the patient has failed or is intolerant of other available osteoporotic therapy An indication that the patient received a single dose of 60 mg/1 ml SQ Prolia which was administered by a healthcare professional into the upper arm, the upper thigh or the abdomen once in 6 months An indication that the patient was instructed to take 1000 mg of calcium and at least 400 IU of vitamin D per day The following are recommended changes for the first three bullets: Bullet #1) An indication that the patient meets the definition of high risk for of fracture, or defined as a history of osteoporotic fracture, or multiple risk factors for fracture, or has failed other available osteoporosis therapy, or is intolerant to other available osteoporosis therapy. (this eliminates the need for bullet #2) Bullet #3) An indication that the patient received a single dose of 60 mg/1 ml SQ Prolia which was administered by a healthcare professional into the upper arm, the upper thigh or the abdomen once in 6 months Contractor response #9: Some of the language was changed for clarification purposes. The language remaining unchanged is from the FDA-approved package insert. Comment #10:
Why should a bedridden patient with a hip fracture and reflux esophagitis have to fail oral therapy with a bisphosphonate to get Prolia or IV Boniva/Reclast? There are many instances where high risk elderly patients should not have to fail oral bisphosphonate drugs to get IV or SQ formulations. Contractor response #10: The medical necessity for the administration of Prolia or IV Boniva/Reclast should be documented in the medical record. The LCD contains criteria that when documented justifies the administration of IV bisphosphonates without failure of prior therapy. Comment #11: Aredia is also a bisphosphonate and should be included in the LCD. Contractor response #11: The LCD only addresses five of the many FDA-approved medications used in the treatment of osteoporosis. Comment #12: Prolia is a biologic agent which must be administered by a healthcare professional and therefore should be considered a complex administration. As long as the providers provide necessary documentation of preparation and administration, J3590 the code for unclassified biologic may be billed along with CPT code 96401 that corresponds to the administration of a biologic/chemo agent. Contractor response #12: The drug administration code has been added to the coding guideline attachment of the LCD. Comment #13: A statement by providers that patients cannot tolerate supplemental calcium/vitamin D should override the requirement for supplementation requirements in the LCD, in appropriate clinical situations. Contractor response #13: The statement regarding supplemental calcium/vitamin D was taken from the FDA-approved package inserts, therefore, the language will not be removed from the LCD. Comment #14:
Please clarify whether Prolia will be covered per package insert as a first line drug, without first having to fail a PO drug, if patients have history of fracture, intolerance or inadequate response to previous treatment, or have multiple risk factors for fracture. Contractor response #14: The medical necessity of the drug and the medical necessity of the route of administration should be justified in the medical record. Comment #15: We received comments regarding coverage for osteopenia, however, the indications for women that fall into the high risk FRAX categories, and are osteopenic and without antecedent fragility fractures, and who are not on mentioned corticosteroids only meet the indication for Prolia as it is the only drug listed in the LCD with an indication of high risk for fracture. There is no ICD-9 code noted referring to high risk patients without osteoporosis other than those being treated for corticosteroids 73309 + E932.0. This holds true for Prolia which has an indication for elevated FRAX. Contractor response #15: The indication listed in this LCD for Prolia is the FDA-approved indication as it is listed in the package insert. Prolia is FDA-approved for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The medical necessity and the indication of the drug and the method of administration should be justified in the medical record. The FRAX information listed in the LCD is not coverage critieria for demonstrating medical necessity for any of the drugs listed in the LCD. Comment #16: The National Osteoporosis Foundation (NOF) Clinical guidelines should be added to the LCD. Contractor response #17: The NOF clinical guidelines were used in the development of this LCD (see references). Comment #17: The LCD states the following: Documentation Requirements For all drugs outlined in this LCD:
Medical record documentation must be maintained by the ordering/referring physician or the nonphysician practitioner and should include the following, and be available to Medicare upon request: The record must demonstrate the medical need for the use of the drug by clearly indicating the condition for which the drug is being used. The medical record must indicate that the treatment is based on diagnostic information and lab work completed to confirm the indications for use of the drug. The specific signs and symptoms must be documented to substantiate the FDA labeled or the FDA off labeled indications for the drug usage. The medical record must indicate that the patient has been examined for secondary causes of osteoporosis. An indication that the patient has been advised to take adequate calcium and vitamin D supplementation. An indication that the patient has been advised to practice regular weight bearing and muscle strengthening exercise to reduce risk of falls and fracture, and to avoid tobacco smoking and excessive alcohol intake. The medication administration record (MAR) including the name, date, time, route and amount of the drug administered to the patient. A statement that demonstrates oral health was discussed with the patient. Recommend that the following changes are made to the LCD: (suggested changes are underlined) Bullet #4) For the osteoporosis indications for drugs outlined in the LCD, the medical record must indicate that the patient has been examined for secondary causes of osteoporosis. Bullet #6) For the osteoporosis indications for drugs outlined in the LCD, An indication that the patient has been advised to practice regular weight bearing and muscle strengthening exercise to reduce risk of falls and fracture, and to avoid tobacco smoking and excessive alcohol intake. Bullet #7) The medication administration record (MAR) including the name, date, time, route and amount dose of the drug administered to the patient. Contractor response #17
Some of the language has been changed to reflect the recommendations. FIRST COAST SERVICE OPTIONS CODING GUIDELINES LCD Database ID Number L32100 Contractor Name First Coast Service Options, Inc. Contractor Number 09102 Florida 09202 Puerto Rico 09302 Virgin Islands LCD Title Bisphosphonates (Intravenous [IV]) and Monoclonal Antibodies in the Treatment of Osteoporosis and Their Other Indications Coding Guidelines Bisphosphonates Reclast HCPCS code J3489 (Injection, zoledronic acid, 1 mg) should be used to report Reclast. The number of units billed on a claim should be 5, since Relcast is given as a single 5 mg injection. Reclast is only administered once per 12 months, therefore, only one Reclast claim should be submitted per year. *Re-treatment of Paget s disease may be considered in patients who have relapsed, based on increases in serum phosphatase, or in patients who fail to achieve normalization of serum alkaline phosphatase, or in patients with symptoms as dictated by current standard medical practice. Zometa HCPCS code J3489 (Injection, zoledronic acid, 1 mg) should be used to report Zometa The number of units billed on a claim should be 4 since Zometa is given as a single 4 mg injection for the indications outlined in the LCD.
Re-treatment of Hypercalcemia of malignancy repeat one dose, of Zometa after a minimum of 7 days following the initial dose Monoclonal Antibodies - RANK ligand (RANKL) Inhibitors: Prolia CPT code 96401 (Chemotherapy administration, subcutaneous or intramuscular; non-hormonal antineoplastic) can be used for the administration of Prolia Prolia is only given twice a year, so, there should only be two claims submitted per 12 months. Xgeva CPT code 96401 (Chemotherapy administration, subcutaneous or intramuscular; non-hormonal antineoplastic) can be used for the administration of Xgeva. The number of units billed on a claim should be 120 since the dosage of Xgeva is 120 mg every four weeks for this indication. An additional 120 mg dose of Xgeva is administered on days 8 and 15 of the first month of therapy for treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity. Comments N/A Revision History Date Revision 01/01/2014 5- Annual 2014 HCPCS Update. Deleted HCPCS code Q2051 and replaced with HCPCS code J3489. The effective date is based on date of service. 10/14/2013 4-Based on the new FDA label indication for Xgeva (treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity), additional dose requirements were added to the Coding Guidelines section, subtitled Xgeva. The effective date of this revision is for claims processed on or after 10/14/2013 for dates of service on or after 06/13/13. 07/01/2013 3-Based on CR 8286 (Quarterly HCPCS Drug/Biological Code Changes-July 2013 Update)/CR 8291 (July Update to the CY 2013 MPFSDB)/CR 8328 (July 2013 Update of the ASC payment System), HCPCS codes J3487 and J3488 received status indicator I (not valid for Medicare purposes) and were replaced with HCPCS code Q2051. The effective date of this revision is based on date of service. 05/01/2012 2-Revised to delete unnecessary information. The effective date of this revision is for claims processed on or after 05/01/2012 for dates of service on or after 10/16/2011. 01/01/2012 1-Annual 2012 HCPCS Update. Deleted Unlisted HCPCS code J3590 and HCPCS code C9272 and replaced with HCPCS code
10/16/2011 Original J0897. Deleted the information regarding billing of the unlisted code. Changed Contractor Determination Number to J0897. The effective date of this revision is based on date of service. Document formatted: 12/12/2013 (MB/et)